Bortezomib extends lung cancer survival

Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to results from a phase II trial led by UC Davis Cancer Center.

In the study, patients taking bortezomib plus gemcitabine and carboplatin had a median survival of 11 months, reported Angela Davies, an assistant professor of hematology and oncology at UC Davis Cancer Center and lead author of the study. In comparison, 9 months is the longest median survival seen in past SWOG trials of platinum-based chemotherapy treatments for advanced non-small cell lung cancer.

“These survival results are among the best ever reported in patients with NSCLC,” Davies said. “We look forward to further study of bortezomib in combination with chemotherapy as treatment for NSCLC in a larger, phase III trial.” In the study, 114 newly diagnosed stage IV and selected stage IIIB patients received gemcitabine and carboplatin in combination with bortezomib. The median overall survival was 11 months; one-year survival was 46 percent, with a median five-month progression-free survival. Other key findings:

 
• 66 percent of patients benefited from the therapy, experiencing tumor shrinkage or disease stabilization  
• The treatment was well tolerated; the most common side effects were neutropenia, a very low white-blood cell count; thrombocytopenia, a very low platelet count; and fatigue.

The study was supported by grants from the National Cancer Institute.

The Southwest Oncology Group is one of the largest National Cancer Institute-supported cancer clinical trials cooperative groups in the United States, with a network of more than 5,000 physician-researchers at nearly 550 institutions. Its lung committee is chaired by David R. Gandara, professor of hematology and oncology and director of the Clinical Research Program at UC Davis Cancer Center.

Lung cancer is the leading cause of cancer death among both men and women in the United States. According to the American Cancer Society, an estimated 174,470 people will be diagnosed with lung cancer this year, and 162,460 will die from it. Non-small cell lung cancer accounts for about 80 percent of lung cancer cases.

Bortezomib, sold under the trade name Velcade, is a small-molecule proteasome inhibitor originally approved as a treatment for multiple myeloma. It was developed by Millennium Pharmaceuticals, Inc., based in Cambridge, Mass.

http://www.ucdmc.ucdavis.edu

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

Profiling approach to enable right lung cancer treatment match   Pfizer lung cancer drug beats chemo for previously untreated patients   Moffitt Cancer Center Researchers Find Potential New Therapeutic Target for Treating Non-Small Cell Lung Cancer   Genome-wide scan maps mutations in deadly lung cancers; reveals embryonic gene link   Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer   Lung Cancer Culprit Could Offer Target for Therapy   Testing lung tumors tailors drug treatments   In Battle Against Lung Cancer, Investigators Eye Oncolytic Virus Therapy   Men who eat soy may have lower lung cancer risk   Lung Cancer Conference Leaders Honor Paul A. Bunn Jr., M.D.   A new mouse could help understand how some lung cancer cells evade drug treatment   Tiny RNA has big impact on lung cancer tumors